TollemarJRingdenO. Lipid formulations of amphotericin B: less toxicity but at what economic cost?Drug Saf1995; 13: 207–18.
2.
RingdenOAndströmERembergerMSvahnBMTollemarJ. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporine. Bone Marrow Transplant1994; 14 (suppl 5): S10–4.
3.
TollemarJRingdenOAndersonSSundbergBLjungmanPTydenG. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant1993; 12: 577–82.
4.
LaingRBSMilneLJRLeenCLSMalcomGPSteersAJ. Anaphylactic reactions to liposomal amphotericin (letter). Lancet1994; 344: 682.
5.
AguadoJMFidalgoMMoyaIAlcazarJMJimémezMJNoriegaAR. Ventricular arrhythmias with conventional and liposomal amphotericin (letter). Lancet1993; 342: 1239.